Obamacare Is Dead – Long Live The ACA
Executive Summary
Making sense of the 'Repeal And Replace' effort in 2017, and thinking through the implications for 2018 and beyond.
You may also be interested in...
Health Reform Endgame: Medicare Advantage For All?
The political dynamics of the health care debate are changing again, and now Democrats are likely to return to universal coverage as a high-profile campaign theme. Is there a US “single-payer” model that might actually work out for biopharma innovators?
US FDA Alzheimer Guidance Update Reflects Changes In Biomarkers – And Leadership
Latest update to draft guidance on early Alzheimer’s drug development is the third iteration of a document first published in 2013. The history of the guidance is a reflection of structural and leadership changes in the neurology review team at FDA.
Biden’s Co-Pay Cap Is Silver Lining For Pharma In Drug Pricing Campaign
President Biden’s call to expand the US Medicare price negotiation program is naturally making headlines from his campaign-year State of the Union Address. But his call for a national cap on co-pays could be an important opportunity for industry in the years to come.